Anti-Neuroleukin/GPI Antibody, clone 10C2.1

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: 0.5 μg/mL of this antibody detected Neuroleukin/GPI in 10 μg of HeLa cell lysate.

Immunohistochemistry Analysis: A 1:2,000 dilution from a representative lot detected Neuroleukin/GPI in human thalamus and rat hindbrain tissues.

Research Category
Neuroscience

Research Sub Category
Signaling Neuroscience

This Anti-Neuroleukin/GPI Antibody, clone 10C2.1 is validated for use in western blotting & IHC (Paraffin) for the detection of Neuroleukin/GPI.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Glucose-6-phosphate isomerase (GPI) alternatively known as Autocrine motility factor (AMF), Neuroleukin (NLK), Phosphoglucose isomerase (PGI), Phosphohexose isomerase (PHI) or Sperm antigen 36 (SA-36) and encoded by the gene name GPI is major enzyme in glycolysis and gluconeogenesis. Glucose-6-phosphate isomerase rearranges glucose-6-phosphate (from the phosphorylation of glucose via hexokinases) into fructose-6-phosphate (F6P) as the second step in glycolysis. Interestingly however, Glucose-6-phosphate isomerase plays an entirely different sort of role outside of the cell than when it is inside being part of glycolysis. When secreted, Glucose-6-phosphate isomerase acts as an autocrine motility factor for various cancers and is critical for metastasis, while when secreted in nervous tissue it acts as a neurotrophic factor for sensory and spinal neurons and in lymphocytes it acts as a lymphokine upon T cell ligand binding and stimulates B cells to secrete immunoglobulin. Mutations in Glucose-6-phosphate isomerase are the second most frequent cause of inherited glycolytic-enzymopathy in humans. This autosomal recessive disorder is characterized by a non-spherocytic anemia of variable severity which can present with neuromuscular dysfunctions defined by muscle weakness and mental retardation.

~58 kDa observed

GST-tagged recombinant protein corresponding to human Neuroleukin/GPI.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Format: Purified

Protein G Purified

Purified mouse monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.